Skip to main content

Marc Miquel Moltó Abad

I am a biologist with experience in both clinical and preclinical research on lysosomal storage diseases. I am intrigued by the clinical complexity of these rare diseases. Their low incidence in the population, the limited knowledge about their pathophysiology and the limitations of their current treatment are important points that needs to be investigated. I am very interested in nanotechnology application as a tool to improve the treatment of these diseases as well as the life quality of these patients.

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Rare diseases
Cross-departmental services

Marc Miquel Moltó Abad

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Rare diseases
Cross-departmental services

I am a biologist with experience in both clinical and preclinical research on lysosomal storage diseases. I am intrigued by the clinical complexity of these rare diseases. Their low incidence in the population, the limited knowledge about their pathophysiology and the limitations of their current treatment are important points that needs to be investigated. I am very interested in nanotechnology application as a tool to improve the treatment of these diseases as well as the life quality of these patients.

I have experience in cell culture, in vitro and in vivo assays and the monitoring of clinical trials. Regarding basic research, I have participated in projects ranging from the field of cancer and telomere dysfunction, to projects about the study of nanoparticles application in order to improve the treatment of a rare metabolic disease (Fabry's disease).

In 2013 I got my Biology’s degree from the Universitat Autònoma de Barcelona and in 2015 I completed an official master's degree in Cytogenetics and Reproductive Biology at the same university where I was able to work on my cell culture skills (derivative publication in Oncotarget). Subsequently, I started to work as a research technician in the Rare Diseases Unit of the Vall d'Hebron University Hospital in Barcelona (2016-2019), where I collaborated in the coordination of research projects and clinical trials focused on a group of rare diseases called lysosomal storage diseases. Consequently, I am a co-author of different scientific publications (8), in specialized journals (Mol Genet Metab, J Clin Med, Orphanet J Rare Dis, J Bone Min Res).

In 2020, I began my journey as a predoctoral researcher in the Delivery and Targeting research group testing nanometric systems for the improvement of current treatment of Fabry disease. As a result, I am a co-author of a review paper (WIRES) and a scientific publication (J Extracel Ves).

Projects

Vesículas extracelulares para el tratamiento de enfermeades lisosomales (Título provisional)

IP: -
Collaborators: Laura García Latorre, Guillem Pintos Morell, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos, Zamira Vanessa Diaz Riascos
Funding agency: Instituto de Salud Carlos III
Funding: 153670
Reference: PI21/00936
Duration: 01/01/2022 - 30/06/2025

SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH..

IP: -
Collaborators: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats, Angels Alcina Mila, Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: EUROPEAN COMMISSION
Funding: 649580
Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018
Duration: 01/04/2019 - 30/09/2023

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Cristina Berastegui Garcia

Cristina Berastegui Garcia

Main researcher
Pneumology
Read more
Laura Vidal Tarrason

Laura Vidal Tarrason

Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Laura Gisbert  Gustemps

Laura Gisbert Gustemps

Psychiatry, Mental Health and Addictions
Read more
Manuel Requena Ruiz

Manuel Requena Ruiz

Postdoctoral researcher
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.